Q4 2024 Management View CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

H.C. Wainwright lowered the firm’s price target on Neurocrine (NBIX) to $185 from $190 and keeps a Buy rating on the shares. FY25 Ingrezza ...

Neurocrine Biosciences Inc (NBIX) reports robust sales growth and strategic investments amid competitive pressures and payer challenges.

BofA lowered the firm’s price target on Neurocrine (NBIX) to $179 from $184 and keeps a Buy rating on the shares after the company reported Q4 ...

Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock ...

Ingrezza (valbenazine) comes hot on the heels of a rival drug from Teva, Austedo (deutetrabenazine) which gained FDA clearance for the treatment of chorea associated with Huntington’s disease ...

Ingrezza (valbenazine) is a brand-name drug that’s prescribed for specific movement disorders in adults. Ingrezza comes as a capsule that’s typically taken once per day. Ingrezza is approved ...

Investing.com -- Shares of Neurocrine (NASDAQ: NBIX) Biosciences (NASDAQ: NBIX) tumbled 11% as the company reported revenues that fell short of estimates. Despite reporting a 26% growth in INGREZZA® ...

Investing.com -- Le azioni di Neurocrine Biosciences (NASDAQ: NBIX) sono crollate dell'11% dopo che l'azienda ha riportato ricavi inferiori alle stime. Nonostante una crescita del 26% nelle vendite ne ...

Neurocrine Biosciences has demonstrated strong financial performance, primarily driven by the success of Ingrezza, its treatment for tardive dyskinesia. With a healthy gross profit margin of 68% ...